多西他赛联合FOLFOX方案治疗进展期胃癌临床疗效观察

摘要

Objective To evaluate the efficacy and toxicity of Docetaxel (DTX) combined with FOLFOX in treating patients with advanced gastric carcinoma. Methods Thirty - two patients were treated with Docetaxel and FOLFOX regimen, (1 cycle= every 3 weeks). Tumor assessment was done after 2 cycles. Results The overall response rate was 37.5 ％, and the median TTP was 6.3 months. Median survival time was 10.4 months. The main toxicity was nyelosuppression, gastroin - testinal tract reaction and phlebitis. Conclusion Docetaxel combined with FOLFOX regimen is active and is less toxic and the regimen can be applied to the first line chemotherapy.%目的 观察多西他赛联合FOLFOX方案治疗进展期胃癌的疗效及不良反应.方法 对32例进展期胃癌行多西他赛联合FOLFOX方案化疗,3周为1周期,完成2个周期后评价疗效.结果 化疗总有效率37.5%,中位疾病进展时间6.3个月,中位生存期10.4个月.不良反应以骨髓抑制、胃肠道反应和静脉炎为主.结论 多西他赛联合FOLFOX方案治疗进展期胃癌有较好的疗效,毒副作用可以耐受,可作为进展期胃癌一线治疗方案.